Microbial translocation and cardiometabolic risk factors in HIV infection

AIDS Research and Human Retroviruses

Volumn 30, Issue 6, 2014, Pages 514-522

  Trøseid, Marius ^a,b   Manner, Ingjerd W ^a   Pedersen, Karin K ^c   Haissman, Judith M ^c   Kvale, Dag ^a,b   Nielsen, Susanne D ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE IMMUNOGLOBULIN; CHLOROQUINE; HYDROXYCHLOROQUINE; INSULIN; PREBIOTIC AGENT; RIFAXIMIN; SEVELAMER;

AGE; BLOOD CLOTTING DISORDER; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INFECTION RISK; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA; MASCULINITY; METABOLIC SYNDROME X; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; THROMBOCYTE DYSFUNCTION; VIRUS PATHOGENESIS; BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASES; COMPLICATION; ENTEROPATHY;

BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASES; HIV ENTEROPATHY; HUMANS; RISK FACTORS;

EID: 84902195782     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0280     Document Type: Review

References (132)

1. Deeks SG HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011;62;141-155.
2. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the DAD Study. AIDS 2010;24;1537-1548.
3. Wolf K, Tsakiris DA, Weber R, Erb P, and Battegay M Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185;456-462. (Pubitemid 34142807)
4. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42;1325-1332.
5. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52;569-576.
6. Blanco JJ, Garcia IS, Cerezo JG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 2006;58;133-139. (Pubitemid 44313383)
7. Seaberg EC, Benning L, Sharrett AR, et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 2010;41;2163-2170.
8. Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr 2009;52;25-31.
9. Schillaci G, De Socio GV, Pucci G, et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008;52;308-313.
10. Schillaci G, De Socio GV, Pirro M, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005;25;2381-2385. (Pubitemid 41552658)
11. Hulten E, Mitchell J, Scally J, Gibbs B, and Villines TC HIV positivity, protease inhibitor exposure and subclinical atherosclerosis A systematic review and meta-analysis of observational studies. Heart 2009;95;1826-1835.
12. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection Carotid intimamedial thickness measurements from the FRAM study. AIDS 2009;24;1841-1849.
13. Currier JS, Taylor A, Boyd F, et al. Coronary heart Disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33;506-512. (Pubitemid 36886080)
14. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart Disease in HIV-infected and HIV-uninfected individuals A population-based cohort study. Clin Infect Dis 2007;44;1625-1631. (Pubitemid 46871511)
15. Klein D, Leyden WA, Xu L, X, Chao C, Horberg MA, Towner WJ, et al. Contribution of immunodeficiency to coronary heart Disease Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Paper #810.
16. Triant VA, Lee H, Hadigan C, and Grinspoon SK Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus Disease. J Clin Endocrinol Metab 2007;92;2506-2512. (Pubitemid 47037350)
17. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010;24;1228-1230.
18. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIVinfected patients in a US health care system. J Acquir Immune Defic Syndr 2012;60;351-358.
19. Periard D, Cavassini M, Taffe P, et al. High prevalence of peripheral arterial Disease in HIV-infected persons. Clin Infect Dis 2008;46;761-767. (Pubitemid 351321563)
20. Sabin CA, d'Arminio MA, Friis-Moller N, et al. Changes over time in risk factors for cardiovascular Disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46;1101-1110. (Pubitemid 351589879)
21. Bozzette SA, Ake CF, Tam HK, Chang SW, and Louis TA Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348;702-710. (Pubitemid 36237039)
22. High KP, Brennan-Ing M, Clifford DB, et al. HIV and aging State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012;60(Suppl 1)S1-18.
23. Thienemann F, Sliwa K, and Rockstroh JK HIV and the heart The impact of antiretroviral therapy A global perspective. Eur Heart J 2013;34;3538-3546.
24. Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil Shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One 2013;8;e59768.
25. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356;1723-1735. (Pubitemid 46658704)
26. Iloeje UH, Yuan Y, L'italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular Disease in HIV-infected patients. HIV Med 2005;6;37-44. (Pubitemid 40268115)
27. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular Disease events in chronic HIV infection. AIDS 2010;24;1509-1517.
28. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular Disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17;1179-1193. (Pubitemid 36667761)
29. Triant VA, Regan S, Lee H, et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010;55;615-619.
30. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular Disease in HIVinfected patients over time The Swiss HIV Cohort Study. HIV Med 2006;7;404-410. (Pubitemid 44123252)
31. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart Disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37;292-298. (Pubitemid 36930361)
32. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart Disease risk in HIV-infected men and women. Clin Infect Dis 2007;45;1074-1081. (Pubitemid 47580361)
33. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular Disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118;e29-e35.
34. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals A nationwide, population-based cohort study. Clin Infect Dis 2013;56;727-734.
35. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165;1179-1184. (Pubitemid 40720744)
36. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009;23;1227-1234.
37. De WS, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. Diabetes Care 2008;31;1224-1229.
38. Van TH and Koblin BA HIV, alcohol, and noninjection drug use. Curr Opin HIV AIDS 2009;4;314-318.
39. Rasmussen LD, Omland LH, Pedersen C, et al. Risk of myocardial infarction in parents of HIV-infected individuals A population-based cohort study. BMC Infect Dis 2010;10;169.
40. Gaardbo JC, Hartling HJ, Gerstoft J, and Nielsen SD Incomplete immune recovery in HIV infection Mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012;2012;670957.
41. Guaraldi G, Orlando G, Zona S, et al. Premature agerelated comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53;1120-1126.
42. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12;1365-1371. (Pubitemid 44924494)
43. Kao CY, Chen Y, Thai P, et al. IL-17 markedly upregulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol 2004;17;33482-3491. (Pubitemid 39142059)
44. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203;2271-2279. (Pubitemid 44498362)
45. Salzman NH, Hung K, Haribhai D, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010;11;76-83.
46. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 2009;58;220-227.
47. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008;112;2826-2835.
48. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4 + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77;11708-11717. (Pubitemid 37271669)
49. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4 + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200;761-770. (Pubitemid 39299462)
50. Brenchley JM, Schacker TW, Ruff LE, et al. CD4 + T cell depletion during all stages of HIV Disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200;749-759. (Pubitemid 39299461)
51. da Silva CJ and Ulevitch RJ MD-2 and TLR4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 2002;277;1845-1854. (Pubitemid 34968758)
52. Latz E, Visintin A, Lien E, et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is Distinct from the initiation of signal transduction. J Biol Chem 2002;277;47834-47843. (Pubitemid 36159310)
53. Troseid M, Lind A, Nowak P, et al. Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection Possible implication for TLR4-signalling and chronic immune activation. Innate Immun 2013;19;290-297.
54. Nowak P, Abdurahman S, Lindkvist A, Troseid M, and Sonnerborg A Impact of HMGB1/TLR ligand complexes on HIV-1 replication Possible role for flagellin during HIV-1 infection. Int J Microbiol 2012;2012;263836.
55. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199;1177-1185.
56. Funderburg N, Luciano AA, Jiang W, et al. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008;3;e1915.
57. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203;780-790.
58. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts Disease progression of HIV-infected antiretroviral-naive patients with high CD4 + cell count. AIDS 2011;25;1385-1394.
59. Dandekar S Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007;410-15. (Pubitemid 46555246)
60. Deeks SG Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009;17;118-123.
61. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV Disease. Science 1997;277;112-116. (Pubitemid 27450659)
62. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396;690-695. (Pubitemid 29003949)
63. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000;95;249-255. (Pubitemid 30017249)
64. Pedersen KK, Pedersen M, Gaardbo JC, et al. Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr 2013;63;272-279.
65. Troseid M, Nowak P, Nystrom J, et al. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection Reduction by 2-year antiretroviral therapy. AIDS 2010;24;1733-1737.
66. Sandler NG and Douek DC Microbial translocation in HIV infection Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10;655-666.
67. Manco M, Putignani L, and Bottazzo GF Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010;31;817-844.
68. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;46;459-65.
69. Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012;3;1245.
70. Burcelin R, Serino M, Chabo C, Blasco-Baque V, and Amar J Gut microbiota and diabetes From pathogenesis to therapeutic perspective. Acta Diabetol 2011;48;257-273.
71. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesityassociated gut microbiome with increased capacity for energy harvest. Nature 2006;444;1027-1031. (Pubitemid 46018515)
72. McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia A novel factor in systemic inflammation and cardiovascular Disease in chronic kidney Disease. Clin J Am Soc Nephrol 2011;6;133-141.
73. Szeto CC, Kwan BC, Chow KM, et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3;431-436.
74. Erridge C, Attina T, Spickett CM, and Webb DJ A highfat meal induces low-grade endotoxemia Evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007;86;1286-1292. (Pubitemid 350126229)
75. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56;1761-1772. (Pubitemid 47025442)
76. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, and Salomaa V Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011;34;392-397.
77. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular Disease Prospective results from the Bruneck Study. J Am Coll Cardiol 1999;34;1975-1981. (Pubitemid 30002653)
78. Troseid M, Nestvold TK, Rudi K, et al. Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity Evidence from bariatric surgery. Diabetes Care 2013;36;3627-3632.
79. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated with obesity and related metabolic Disorders in apparently healthy Chinese. Diabetes Care 2010;33;1925-1932.
80. Caesar R, Reigstad CS, Backhed HK, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 2012;61;1701-1707.
81. Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes Molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3;559-572.
82. Fei N and Zhao L An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013;7;880-884.
83. Lew WY, Bayna E, Molle ED, et al. Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS One 2013;8;e61057.
84. Baker JV, Peng G, Rapkin J, et al. CD4 + count and risk of non-AIDS Diseases following initial treatment for HIV infection. AIDS 2008;22;841-848. (Pubitemid 351563833)
85. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4 + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009;48;787-794.
86. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4 + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187;1534-1543. (Pubitemid 36578959)
87. Pandrea I, Cornell E, Wilson C, et al. Coagulation biomarkers predict Disease progression in SIV-infected nonhuman primates. Blood 2012;120;1357-1366.
88. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4 + T cell count is a risk factor for cardiovascular Disease events in the HIV outpatient study. Clin Infect Dis 2010;51;435-447.
89. Manner IW, Troseid M, Oektedalen O, Baekken M, and Os I Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals. J Clin Hypertens (Greenwich) 2013;15;101-106.
90. Manner I, Baekken M, Kvale D, et al. Markers of microbial translocation predict hypertension in HIV-infected individuals. HIV Med 2013;14;354-361.
91. Pedersen KK, Pedersen M, Troseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr 2013;64;425-433.
92. Byakwaga H, Hsue P, Sambrano E, and Sinclair E Background subtraction in the limulus subtraction amebocyte assay may underestimate lipopolysaccharide levels in those with the greatest microbial translocation. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Paper #783.
93. Timmons T Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection. AIDS Res Hum Retroviruses 2014;30;272-277.
94. Ghoshal S, Witta J, Zhong J, de VW, and Eckhardt E Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009;50;90-97.
95. Levine DM, Parker TS, Donnelly TM, Walsh A, and Rubin AL In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993;90;12040-12044. (Pubitemid 24008776)
96. Casanovas A, Carrascal M, Abian J, Lopez-Tejero MD, and Llobera M Lipoprotein lipase is nitrated in vivo after lipopolysaccharide challenge. Free Radic Biol Med 2009;47;1553-1560.
97. Cassol E, Misra V, Holman A, et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 2013;13;203.
98. Manner IW, Baekken M, Oektedalen O, et al. Plasma LPS and triglycerides are independently associated, and both markers correlate with the development of metabolic syndrome in HIV infection. J Acquir Immune Defic Syndr 2014;65;158-161.
99. Matta F, Yaekoub AY, and Stein PD Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 2008;33;6402-406.
100. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5;e203.
101. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection Relationship to in vivo coagulation and immune activation. Blood 2010;115;161-167.
102. Mayne E, Funderburg NT, Sieg SF, et al. Increased platelet and microparticle activation in HIV infection Upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012;59;340-346.
103. Haugaard AK, Lund TT, Birch C, et al. Discrepant coagulation profile in HIV infection Elevated D-dimer but impaired platelet aggregation and clot initiation. AIDS 2013;27;2749-2758.
104. Ross R Atherosclerosis-an inflammatory Disease. N Engl J Med 1999;340;115-126.
105. Verma S and Anderson TJ Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002;105;546-549. (Pubitemid 34123425)
106. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, and Heine H TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002;56;126-134. (Pubitemid 35247809)
107. Manner IW, Baekken M, Os I, Kvale D, Seljeflot I, and Troseid M Symmetric and asymmetric dimethylarginine are associated with plasma LPS, low nadir CD4 count and future hypertension in HIV-infection. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract #786.
108. Parikh RV, Scherzer R, Grunfeld C, et al. Elevated levels of asymmetric dimethylarginine are associated with lower CD4 + count and higher viral load in HIV-infected individuals. Atherosclerosis 2013;229;246-252.
109. Blodget E, Shen C, Aldrovandi G, et al. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One 2012;7;e42624.
110. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92;1355-1374.
111. KelesiDis T, Kendall MA, Yang OO, HoDis HN, and Currier JS Biomarkers of microbial translocation and macrophage activation Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012;206;1558-1567.
112. Merlini E, Luzi K, Suardi E, et al. T-cell phenotypes, apoptosis and inflammation in HIV + patients on virologically effective cART with early atherosclerosis. PLoS One 2012;7;e46073.
113. Weidemann B, Schletter J, Dziarski R, et al. Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Infect Immun 1997;65;858-864. (Pubitemid 27087982)
114. Karlsson F, Tremaroli V, Nielsen J, and Backhed F Assessing the human gut microbiota in metabolic Diseases. Diabetes 2013;62;3341-3349.
115. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498;99-103.
116. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368;1575-1584.
117. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19;576-585.
118. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2011;57;363-370.
119. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV Disease progression and tryptophan catabolism. Sci Transl Med 2013;51;93ra91.
120. Pedersen ER, Svingen GF, Schartum-Hansen H, et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J 2013;34;2689-2696.
121. Lam YY, Ha CW, Campbell CR, et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012;7;e34233.
122. Stinghen AE, Goncalves SM, Bucharles S, et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010;29;352-356.
123. Murray SM, Down CM, Boulware DR, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84;12082-12086.
124. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011;118;3263-3272.
125. Kalambokis GN and Tsianos EV Rifaximin reduces endotoxemia and improves liver function and Disease severity in patients with decompensated cirrhosis. Hepatology 2012;55;655-656.
126. Asmuth DM, Ma ZM, Albanese A, et al. Oral serumderived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS 2013;27;2207-2217.
127. Gori A, Rizzardini G, van't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults Results of the "COPA" pilot randomized trial. Mucosal Immunol 2011;45;54-563.
128. Vrieze A, Van NE, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143;913-916.
129. Troseid M, Pedersen B, Ditlevsen S, et al. Decreased trunk fat and triglycerides after strength training are associated with reduced LPS levels in HIV-infected individuals. J Acquir Immune Defic Syndr 2014; in press.
130. Kallio KA, Buhlin K, Jauhiainen M, et al. Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun 2008;14;247-253.
131. Funk JL, Feingold KR, Moser AH, and Grunfeld C Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis 1993;98;67-82. (Pubitemid 23010425)
132. Kallio KA, Hyvarinen K, Kovanen PT, Jauhiainen M, and Pussinen PJ Very low density lipoproteins derived from periodontitis patients facilitate macrophage activation via lipopolysaccharide function. Metabolism 2013;62;661-668.